文献速递浆细胞疾病

可溶性BCMA定义新诊断多发性骨髓瘤的空间表型与预后

Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma.
PubMed 文献 · Blood · 2026-09-22

该研究纳入352例新诊断多发性骨髓瘤患者,整合骨髓浆细胞比例、MRI总扩散体积、PET代谢肿瘤体积及血清sBCMA水平,通过主成分分析和无监督聚类划分出四种空间表型。sBCMA升高而非肿瘤体积是早期治疗失败的主要决定因素,Gain(1q21)的预后影响因表型而异。

要点

  • sBCMA较影像学肿瘤体积更能预测早期治疗失败。
  • Sero-dominant与Dual-High表型12个月PFS相似,尽管肿瘤体积差异显著。
  • Gain(1q21)仅在Sero-dominant表型中与生存不良强相关。

核心结论

  • 多发性骨髓瘤结局由物理肿瘤体积与sBCMA水平的交互作用决定,基于此的多模态分类为风险分层提供合理框架。

研究设计与样本

  • 研究纳入352例新诊断多发性骨髓瘤患者,使用全切片图像量化骨髓浆细胞比例、MRI总扩散体积、PET代谢肿瘤体积及血清sBCMA水平。
  • 在完整数据集患者中,采用主成分分析和无监督聚类,基于物理肿瘤体积和sBCMA水平两个因素将患者分为四种表型。

主要发现

  • 四种表型为Dual-High(高体积/高sBCMA)、Sero-dominant(低体积/高sBCMA)、Macro-dominant(高体积/低sBCMA)和Dual-Low(低体积/低sBCMA)。
  • 在所有评估标志物中,sBCMA显示出最强且最一致的预后关联,独立于影像学定义的肿瘤体积。
  • sBCMA升高而非肿瘤体积是早期治疗失败的主要决定因素;Sero-dominant和Dual-High组尽管肿瘤体积显著不同,12个月无进展生存率相似。
  • Macro-dominant表型代表「空间隔离」状态,影像学肿瘤负荷广泛但局限于解剖位置,无血行播散或髓外扩散。
  • 在Macro-dominant表型中Gain(1q21)的预后影响不显著,而在Sero-dominant表型中与生存不良强相关。

临床怎么用

  • 可结合sBCMA水平与影像学肿瘤体积对初诊多发性骨髓瘤患者进行多模态风险分层。
  • 对Sero-dominant表型患者应关注Gain(1q21)的预后不良影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In multiple myeloma (MM), defining tumor burden is difficult because systemic bone marrow disease and focal lesions often show different levels of activity. We analyzed 352 newly diagnosed patients. We used bone marrow plasma cell percentage (BMPC) quantified from whole slide images, MRI-total diffusion volume (TDV), PET-metabolic tumor volume (TMTV), and serum sBCMA levels. In patients with complete datasets, Principal Component Analysis (PCA) and unsupervised clustering were used to classify patients into four phenotypes based on two factors: physical tumor volume (based on BMPC, TDV and TMTV) and sBCMA levels. Among all markers evaluated, sBCMA showed the strongest and most consistent prognostic association, independent of imaging-defined tumor volume. The four phenotypes were: Dual-High (high volume / high sBCMA), Sero-dominant (low volume / high sBCMA), Macro-dominant (high volume / low sBCMA), and Dual-Low (low volume / low sBCMA). Elevated sBCMA, rather than tumor volume, was the primary determinant of early treatment failure; the Sero-dominant and Dual-High groups showed similar 12-month progression-free survival despite markedly different tumor volumes. The Macro-dominant phenotype represented a state of "spatial sequestration," characterized by extensive imaging-defined tumor burden that remained anatomically confined without hematogenous dissemination or extramedullary spread. In this phenotype, the prognostic impact of Gain(1q21) was not significant, whereas it was strongly associated with inferior survival in the Sero-dominant phenotype. MM outcomes are determined by the interaction between physical tumor volume and sBCMA levels. This multimodal classification provides a rational framework for risk stratification.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Toho M, Tabata R, Ikeda D, et al. Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma. Blood. 2026. PMID: 42771591. doi:10.1182/blood.2026033768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。